Ruxolitinib in addition to standard of care for the treatment of patients admitted to hospital with COVID-19 (RUXCOVID): a randomised, double-blind, placebo-controlled, phase 3 trial

MeiLan K. Han, Martti Antila, Joachim H. Ficker, И. Г. Гордеев, Alfredo G. Guerreros, Amparo López‐Bernús, Antoine Roquilly, José Sifuentes‐Osornio, Fehmı Tabak, Ricardo Teijeiro, Lorraine Bandelli, Diane S Bonagura, Xu Shu, James M. Felser, Barbara Knorr, Weihua Cao, Peter Langmuir, Thomas Lehmann, Michael P. Levine, Sinisa Savic